AnaptysBio (NASDAQ:ANAB) had its price target increased by equities research analysts at Royal Bank of Canada to $108.00 in a report released on Monday, December 18th. The brokerage presently has an “outperform” rating on the biotechnology company’s stock. Royal Bank of Canada’s price target suggests a potential downside of 2.00% from the company’s previous close.
ANAB has been the topic of several other reports. SunTrust Banks began coverage on shares of AnaptysBio in a report on Wednesday, November 15th. They issued a “buy” rating and a $115.00 price objective on the stock. Zacks Investment Research lowered shares of AnaptysBio from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Robert W. Baird set a $69.00 target price on shares of AnaptysBio and gave the stock a “buy” rating in a research note on Wednesday, October 11th. Credit Suisse Group upped their price target on AnaptysBio from $38.00 to $85.00 and gave the company an “outperform” rating in a report on Tuesday, October 10th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $75.00 price target (up from $37.00) on shares of AnaptysBio in a report on Friday, October 13th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $88.00.
AnaptysBio (NASDAQ ANAB) traded down $1.09 during trading hours on Monday, hitting $110.20. 262,730 shares of the stock traded hands, compared to its average volume of 366,754. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.77 and a current ratio of 10.77. The stock has a market cap of $2,530.00 and a price-to-earnings ratio of -72.98. AnaptysBio has a 52-week low of $15.17 and a 52-week high of $114.47.
Several institutional investors have recently added to or reduced their stakes in ANAB. TIAA CREF Investment Management LLC purchased a new stake in shares of AnaptysBio during the first quarter worth approximately $227,000. Geode Capital Management LLC purchased a new stake in shares of AnaptysBio during the first quarter worth approximately $1,522,000. Bank of America Corp DE purchased a new position in AnaptysBio in the first quarter worth $123,000. Schwab Charles Investment Management Inc. raised its position in AnaptysBio by 94.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 19,402 shares of the biotechnology company’s stock worth $465,000 after acquiring an additional 9,414 shares in the last quarter. Finally, Alps Advisors Inc. purchased a new position in AnaptysBio in the second quarter worth $436,000. Institutional investors and hedge funds own 75.48% of the company’s stock.
AnaptysBio Company Profile
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.